US App. No. 10/517,328
Response to 12/14/07 Office Action

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-12 (Canceled)

13. (Withdrawn) A method of specifically inhibiting Rsk activity, said method comprising the step of contacting a Rsk enzyme with a compound represented by the general structure:



III

wherein R is H or OH, and R_1, R_2 and R_3 are independently selected from the group consisting of hydroxy -$OCOR_4$, -COR_4 and C_1-C_4 alkoxy; and

R_4 is H or C_1-C_4 alkyl.

14. (Withdrawn) The method of claim 13, wherein R is H or OH and R_1, R_2 and R_3 are independently selected from the group consisting of hydroxy and -$OCOCH_3$.

15. (Withdrawn) The method of claims 13 or 14 wherein R is H.

16. (Withdrawn) The method of claims 13, 14 or 15, wherein R_3 is -$OCOCH_3$.

17-20. (Canceled).

21. (Currently Amended) A method for treating a cancer characterized by excessive Rsk activity, said method comprising the step of administering to a human or other mammal, ~~in~~

~~need thereof~~ having a cancer characterized by excessive Rsk activity and selected from the group consisting of breast, prostate, leukemia, lung, colon, brain, melanoma, ovarian, and kidney, a composition comprising a compound represented by the general structure:



III

wherein R is H or OH, and R_1, R_2 and R_3 are independently selected from the group consisting of hydroxy, -$OCOCH_3$, -$COCH_3$, C_1-C_4 alkoxy, -O-glucoside and -O-rhamnoside in an amount effective for specifically inhibiting Rsk activity in the cells of said human or mammal.

22. (Original) The method of claim 21 wherein R is H and R_1, R_2 and R_3 are independently selected from the group consisting of hydroxy and -$OCOCH_3$.

23. (Original) The method of claim 21 wherein R is H or OH, R_1 and R_2 are independently hydroxy or -$OCOCH_3$ and R_3 is -$OCOCH_3$.

24. (Original) The method of claim 23 wherein R is H.

25. (Currently Amended) A method for treating a cancer characterized by excessive Rsk activity, said method comprising the step of administering to a patient, ~~in need thereof~~ having a cancer characterized by excessive Rsk activity and selected from the group consisting of breast, prostate, leukemia, lung, colon, brain, melanoma, ovarian, and kidney, a composition comprising a Rsk specific inhibitor in an amount effective for specifically inhibiting Rsk activity.

26. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises a compound selected from the group consisting of an anti-sense oligonucleotide and an interfering oligonucleotide.

27. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises an interfering oligonucleotide directed against Rsk1, Rsk2, Rsk3 or Rsk4.

28. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises an extract from the tissues of *Forsteronia refracta* or *Zingiber zerumbet.*

29-31. (Canceled)

32. (Currently Amended) The method of claim ~~21~~ 25 further comprising the steps of administering said ~~human or other mammal~~ patient an additional anti-tumor therapy.

33-50 (Canceled)

51. (Previously presented) The method of claim 21, wherein said cancer is selected from the group consisting of breast cancer, prostate cancer, and sarcoma.

52. (Previously presented) The method of claim 51, wherein said Rsk inhibitor is selected from the group consisting of SL0101-1, SL0101-2, and SL0101-3, having the following structures:



SL0101-1



SL0101-2

and



SL0101-3

53. (Previously presented) The method of claim 25, wherein said cancer is selected from the group consisting of breast cancer, prostate cancer, and sarcoma.